Radius nabs $43M round for PhIII bone-building drug

Radius Health joined the lineup of biotechs announcing big new venture rounds today. The Cambridge, MA-based developer, which is focused on new therapies for osteoporosis, says that F2 Biosciences III stepped up to lead the latest round of $43 million. The money will be spent on Radius's lead asset, BA058, a bone-building compound in late-stage development. The injectable BA058-SC is currently in a Phase III trial while BA058-TD is in a Phase II trial designed to study the "efficacy of delivering BA058 via a transdermal patch." Biotech Growth N.V., MPM Capital, Brookside Capital, MPM Bio IV NVS Strategic Fund and BB Biotech Ventures all joined the round, demonstrating the enthusiasm in venture circles for late-stage products. Release